


3D Neurotoxicity Assay: Human brain microtissues.

Background Information



'HCA can be used to precisely distinguish between neuron-specific toxicity and general cytotoxicity while simultaneously enabling inclusion of other parameters to detect novel neurotoxic effects of chemicals.'

¹ Wilson MS *et al.*, (2014)
NeuroToxicology **42**; 33-48

- The prevalence of adverse neurotoxic reactions of the brain in response to drugs or environmental hazards continues to prompt the development of novel cell-based assays for accurate neurotoxicity prediction¹.
- *In vitro* three-dimensional (3D) cell cultures allow better recapitulation of the complex *in vivo* microenvironment than traditional 2D monolayer models².
- 3D models also permit long-term compound exposures allowing a closer replication of clinical dosing strategies³.
- Mitochondrial dysfunction and calcium homeostasis⁴ are commonly observed responses to toxic compounds and are implicated in neurotoxicity.
- Confocal high content imaging (HCI) allows the simultaneous detection of multiple cell health parameters within a 3D microtissue structure in combination with a measure of cellular ATP content.

Protocol

Microtissue

Included pluripotent stem cell (iPSC) derived neurocytes and astrocytes.

Analysis Platform

Confocal Cellomics ArrayScan® XTI or CX7 (Thermo Scientific).

Test Compound Concentrations

8 point dose response curve with top concentration based on 100x C_{max} or solubility limit. 3 replicates per concentration.*

Compound Requirements

Maximum (dependent upon number of repeat doses) 150 µL of a DMSO* solution to achieve 200x top concentration maintained at 0.5% DMSO or equivalent amount in solid compound.

Time Points

Any time point up to 14 days.

Quality Controls

Negative control: 0.5% DMSO (vehicle)
Positive controls: chloroquine and colchicine


Data Delivery

Minimum effective concentration (MEC) and AC₅₀ value for each measured parameter; microtissue count, microtissue size, DNA structure (DNA), calcium homeostasis (Ca²⁺) mitochondrial mass (Mito Mass), mitochondrial membrane potential (MMP) and cellular ATP content (ATP)*.

*Other options available on request

Figure 1

Representative 3D confocal high content screening (HCS) images of brain microtissues labelled with Hoechst (Blue; DNA structure and microtissue size), Fluo-4 AM (Green; calcium homeostasis) and TMRE (Red; mitochondrial function) following exposure to either control DMSO or effective concentrations of known neurotoxins chloroquine, colchicine and lead acetate.

**Table 1**


Neurotoxicity prediction of 10 reference compounds categorised according to literature data and normalized to total plasma C_{max} in immature and matured brain microtissues.

| Name | Expected outcome | Top conc (μM) | C_{max} (μM) | 72 hour (AC_{50}) | | 336 hour (AC_{50}) | |
|--|------------------|----------------------------|-----------------------------|-----------------------|------------------|------------------------|------------------|
| | | | | Immature brain MT | Matured brain MT | Immature brain MT | Matured brain MT |
| Amoxicillin | Non-toxic | 100 | 0.87 | 43.6 | NR | NR | NR |
| Acetaminophen | Non-neurotoxic | 15000 | 130 | 8790 | 13800 | 6450 | 3230 |
| Acrylamide | Neurotoxic | 10 | 0.029 | 4.26 | NR | 0.235 | NR |
| Chloroquine diphosphate | Neurotoxic | 200 | 1.62 | 52.5 | 28.2 | 13.1 | 13.1 |
| Colchicine | Neurotoxic | 2 | 0.015 | 0.0138 | 0.00954 | 0.00748 | 0.00488 |
| Lead acetate | Neurotoxic | 200 | 1.3 | NR | NR | NR | 23.1 |
| Lidocaine | Neurotoxic | 3000 | 25.6 | NR | NR | 1650 | 2120 |
| Paclitaxel | Neurotoxic | 200 | 2 | 45.4 | 16.7 | 11.8 | <0.08 |
| Tamoxifen | Neurotoxic | 10 | 0.083 | NR | 9.45 | 6.37 | 5.45 |
| Vinblastine sulfate | Neurotoxic | 20 | 0.24 | 0.0429 | <0.008 | <0.008 | <0.008 |
| Correct prediction within 100x C_{max} or solubility limit | | | | 50% | 60% | 80% | 80% |

Immature (3 day old) or matured (14 day old) brain microtissues were exposed to test compound for 72 or 336 hrs. During the 336 hr period re-dosing occurred on 3 occasions (72, 168 and 210 hr). At either 72 or 336 hr the cell model was analysed using the confocal mode of Cellomics ArrayScan® XTI or CX7 (Thermo Scientific) following incorporation of fluorescent dyes. Cellular ATP content was subsequently measured using CellTiterGlo® (Promega).

Figure 2

Graphical representation of early calcium dyshomeostasis followed by a decrease in microtissue size in response to colchicine following (a) 72 hours and (b) 336 hours in brain microtissues.



Utilising the 3D neurotoxicity assay approach 80% of reference compound toxicities were correctly predicted within a 100x C_{max} cut off with a 336 hour exposure period in both immature and matured brain microtissues. Following the acute time point of 72 hour compound exposure, only 50% and 60% of compounds were correctly predicted within a 100x C_{max} cut off in the immature and matured brain microtissues, respectively.

An *in vitro* 3D brain microtissue model with improved longevity and better recapitulation of *in vivo* cellular physiology in combination with an automated multiparametric HCS and a cytotoxicity assay presents a viable screening strategy for the accurate *in vivo* relevant detection of novel therapeutics with neurotoxicity potential early in drug development.

References

- Wilson MS *et al.*, (2014) Multiparametric high content analysis for assessment of neurotoxicity in differentiated neuronal cell lines and human embryonic stem cell-derived neurons. *Neurotoxicology* **42**; 33-48
- Anderl JL *et al.*, (2009) A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity. *J Vis Exp* **27**; e1173
- Pamies D *et al.*, (2017) A human brain microphysiological system derived from induced pluripotent stem cells to study neurological diseases and toxicity. *ALTEX* **34**(3); 362-376
- Guo GW & Liang YX (2001) Aluminium-induced apoptosis in cultured astrocytes and its effect on calcium homeostasis. *Brain Res* **888**; 221-226